The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | Upcoming regimens in MCL
Natalie Grover, MD, UNC School of Medicine, Chapel Hill, NC, discusses regimens on the horizon in mantle cell lymphoma (MCL). Upcoming treatment strategies include CAR T-cell therapies, such as lisocabtagene maraleucel, bispecific CAR T-cells targeting CD19 and CD20, as well as combinations with CAR-T and Bruton’s tyrosine kinase (BTK) inhibitors. Additionally, pirtobrutinib, a non-covalent BTK inhibitor, has shown promising results in patients with relapsed/refractory MCL. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Disclosures
Consulting: Tessa and Novartis
Advisory board: ADC therapeutics and Kite
Research funding: Genentech
